Study of SacubitrilValsartan to Improve Insulin Sensitivity and Metabolic Health in Black Adults at Risk for Cardiometabolic Disease

What this Trial Is About

Black individuals often have reduced insulin sensitivity, increasing their risk for cardiometabolic diseases like diabetes. This study evaluates whether increasing levels of natriuretic peptides NPs, hormones produced by the heart that influence metabolism, can improve metabolic health in Black individuals. The study focuses on the role of low NP levels in contributing to higher diabetes risk and tests the effects of NP augmentation through medication. Participants will be randomly assigned to receive either sacubitrilvalsartan, which increases NP levels by inhibiting the enzyme neprilysin, or valsartan alone. Both medications are taken twice daily for 12 weeks. The study compares changes in insulin sensitivity, energy expenditure at rest and during exercise, and post-meal hormone responses between the two groups. Assessments include intravenous glucose tolerance tests, standardized meal tests, and treadmill exercise protocols. During the trial, participants will be evaluated at the start and after 12 weeks of treatment to measure insulin sensitivity, energy use, and hormone levels related to metabolism. Various blood tests and exercise capacity measurements will be performed to monitor changes. The research also tracks safety and metabolic health markers to understand the impact of NP augmentation on cardiometabolic risk in Black adults.

NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals